US 10/553,661

12/13

REMARKS

RECEIVED
CENTRAL FAX CENTER
AUG 1 6 2007

I. Amendments

Claims 69-78 are added. Claims 69-75 correspond to claims 3, 4, 8, 57-59 and 61 but depend on claim 2. Claims 76-78 are similar to claims 4, 72 and 65 but recite "lung cancer".

The amendments do not add subject matter beyond the application as originally filed. Entry of the amendments by the Examiner is respectfully requested.

II. Drawings

No colour drawings are submitted. The description of Figure 6 on page 15 does not refer to a drawing in the application (see below).

III. Specification

Errors in the specification are corrected. Specifically, the reference to a colour version of Figure 6 is moved from page 15 to page 86 and made explicit that the colour version is not shown.

The trademarks are identified, accompanied by generic terminology, as required.

IV. Claim Objections

Claim 10 is amended to delete reference to the non-elected "mRNA" subject matter.

V. Rejection under 35 USC § 112, 2nd paragraph

Claims 59 and 61 are amended to state that the antibody is "specifically immunoreactive to hPygo2 protein". As amended, the claims are definite.

US 10/553,661

13/13

RECEIVED CENTRAL FAX CENTER

AUG 1 6 2007

VI. Rejection under 35 USC § 112, 1st paragraph

The Examiner rejects claims 1-4, 8, 10, 57-59, 61, 62 and 64-68, asserting that "the specification, while being enabling for detecting hPygo2 protein in ovarian, breast, cervical and lung cancer, does not reasonably provide enablement for detecting hPygo2 protein in just any cancer". Applicants submit that the claims as amended state that "the cancer is at least one of cervical cancer, breast cancer, ovarian cancer and lung cancer". The claims are cnabled and the Examiner is requested to withdraw the rejection.

VII. Final Remarks

Consideration and favourable action on all pending claims are respectfully requested. If any questions or issues remain, the Examiner is invited to contact the undersigned at the telephone number set forth below so that a prompt disposition of this application can be achieved.

If there are any fees due in connection with the filing of this Amendment, please charge the fees to our Deposit Account Number 19-2550.

In view of the foregoing, early favourable consideration of this application is earnestly solicited.

Respectfully submitted,

SMART & BIGGAR

P.O. Box 2999, Station D 900-55 Metcalfe Street

Ottawa, Ontario Canada K1P 5Y6

Tel: (613) 232-2486 x243 Fax: (613) 232-8440

Date: August 16, 2007